Peptides DB
Research-centric peptide and protocol reference hub
Study 9 of 10GHRP-2 (Pralmorelin) literatureThe Journal of clinical endocrinology and metabolism · RCTHigh-impact journal2011

Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and men.

This study found that gender and sex-steroid supplementation significantly affect growth hormone recovery from autoinhibition, with distinct effects based on the type of secretagogue used.

Read at The Journal of clinical endocrinology and metabolismAdd to compare

Where it sits

this study against the rest of the ghrp-2 (pralmorelin) corpus
0
Preclinical
9
Observational
0
Open-label
1
Randomised · this one
0
Reviews

Summary and findings

This study measured the effects of gender, sex-steroid supplementation, and secretagogue type on growth hormone (GH) recovery from autoinhibition in 10 healthy postmenopausal women and 10 comparably aged men. Participants underwent a double-blind, crossover treatment with either testosterone or estradiol versus placebo, following an intravenous pulse of GH. The findings indicated that both nadir and peak GH levels were significantly influenced by the type of peptide administered.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Nadir GH and peak GH during feedback were enhanced by GHRH or GHRP-2 (P < 0.001 for both).2011

Abstract

The authors’ words, as The Journal of clinical endocrinology and metabolism supplied them

<h4>Context</h4>GH negatively regulates its own secretion. How gender, sex steroids, and secretagogues modulate GH autofeedback is not known.<h4>Hypothesis/objective</h4>Supplementation with sex steroids and/or a peptidyl secretagogue will enhance the escape of GH from autoinhibition, thus framing a mechanism for amplifying pulsatile GH secretion.<h4>Subjects and setting</h4>Ten healthy postmenopausal women and 10 comparably aged men participated at the Clinical-Translational Science Unit.<h4>Design/interventions</h4>Randomly ordered, double-blind, prospective crossover treatment with placebo vs. testosterone (men) or placebo vs. estradiol (women). Autofeedback was imposed by an iv pulse of GH. Recovery of feedback inhibition was quantified during constant infusion of saline, GHRH, or GH-releasing peptide-2 (three peptide categories).<h4>Outcomes/results</h4>During negative feedback, total (integrated) GH recovery depended upon gender (P = 0.017), sex hormone (P < 0.001), and peptide category (P < 0.001). Mechanistic analysis revealed that feedback-suppressed nadir GH concentrations were determined by sex-steroid treatment (P = 0.018) but not by gender (P = 0.444). Peak GH escape was controlled by both treatment (P = 0.004) and gender (P = 0.003). Nadir GH and peak GH during feedback were enhanced by GHRH or GHRP-2 (P < 0.001 for both). Gender × peptide (P = 0.012 for nadir GH), treatment × peptide (P < 0.001 total and peak GH), and gender × treatment (P = 0.017 nadir GH) regulated GH recovery interactively.<h4>Conclusion</h4>Gender, sex-steroid supplementation, and secretagogue type confer distinct feedback-rescuing effects, introducing a new level of complexity in the control of pulsatile GH regulation.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the GHRP-2 (Pralmorelin) corpus

BFactors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp.The Journal of clinical endocrinology and metabolism · 2009 · 1.4-fold more GH release with l-arginine/GHRH in young than older men, P = 0.021.HumanBEmergence of carbapenem-resistant putative hypervirulent &lt;i&gt;Klebsiella pneumoniae&lt;/i&gt; ST147 with a distinct hybrid plasmid in Türkiye.Emerging microbes & infections · 2026 · 33.1% CR-hvKp among CR-Kp by 2023.HumanBAssociation between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.europepmc · 2022 · n=50 · Overweight (odds ratio, 3.86; 95% confidence interval, 1.02-14.66).HumanCSystemic infusion of exogenous ghrelin in male broiler chickens (Gallus gallus domesticus). The effect of pulse frequency, doses, and ghrelin forms on feed intake, average daily gain, corticosterone, and growth hormone concentrations.europepmc · 2022 · Linear decrease in FI with AG infusion, P=0.002.AnimalBEffect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels.europepmc · 2023 · n=30 · Peak GH significantly and negatively predicted hs-CRP levels (β = -0.345; 95% CI, -0.533 to -0.158).HumanBPembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.europepmc · 2024 · n=1 · Not reported in abstract.Human